Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://francisa862dbi2.bloggip.com/profile